oral vs subcutaneous semaglutide Assessment of noninferiority of semaglutide: a systematic review and meta-analysis oral vs subcutaneous semaglutide What

Casi el 40% de los pacientes que toman frmacos de segunda lnea para la diabetes interrumpen el tratamiento, pero este nmero es incluso mayor (50%) entre los que toman GLP-1

In more serious cases, it can affect the heart muscle or liver

Risk factors for developing blood clots include having a history of DVT or pulmonary embolism, long periods of sitting or bed rest, such as during long flights or hospital stays, being overweight, having a family history of blood clots or clotting disorders, having inherited conditions like Factor V Leiden mutation, being over 60 years of age, or having diabetes

That has major implications for scalability and chronic disease management, especially outside major healthcare systems